Athersys to Present at 2019 Cell & Gene Meeting on the Mesa
September 25 2019 - 8:00AM
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van
Bokkelen, Chairman and CEO, will present at the annual Cell &
Gene Meeting on the Mesa to be held October 2nd -4th in Carlsbad,
California.
Dr. Van Bokkelen will provide a brief overview
of the Company’s mission and its therapeutic platform, MultiStem®
cell therapy. The presentation will include information on the
critical care indications in the Company’s progressing clinical
pipeline, including the ongoing Phase 3 trial of MultiStem cell
therapy for the treatment of ischemic stroke that has received Fast
Track and Regenerative Medicine Advanced Therapy designation from
the U.S. Food and Drug Administration and positive scientific
advice from the European Medicines Agency, and is being conducted
under a Special Protocol Assessment. The presentation will also
cover the Company’s Acute Respiratory Distress Syndrome (“ARDS”)
program, which has received Fast Track designation from the U.S.
Food and Drug Administration.
Organized by the Alliance for Regenerative
Medicine, the Cell & Gene Meeting on the Mesa is a three-day
conference featuring more than 80 dedicated company presentations
by leading public and private companies, highlighting technical and
clinical achievements over the past 12 months in the areas of cell
therapy, gene therapy, gene editing, tissue engineering and broader
regenerative medicine technologies, as well as over 100 panelists
and featured speakers.
The following are specific details regarding the Athersys
presentation at the conference:
Event: |
Athersys Corporate Presentation |
Date: |
Thursday, October 3, 2019 |
Time: |
5:45 p.m. Pacific Time |
Location: |
BlueRock Therapeutics Ballroom, Park Hyatt Aviara Resort, 7100
Aviara Resort Dr., Carlsbad, CA 92011 |
A live video webcast of all company presentations will be
available at: http://www.meetingonthemesa.com/webcast and will also
be published on the conference website and the Athersys website
shortly after the event.
Please visit www.meetingonthemesa.com for full information,
including registration. Complimentary attendance at this event is
available for credentialed investors and members of the media,
only. Investors should contact Laura Parsons at
lparsons@alliancerm.org, and interested media should contact
Lyndsey Scull at lscull@alliancerm.org.
About MultiStem
MultiStem cell therapy is a patented regenerative medicine
product in clinical development that has shown the ability to
promote tissue repair and healing in a variety of ways, such as
through the production of therapeutic factors produced in response
to signals of inflammation and tissue damage. MultiStem therapy’s
potential for multidimensional therapeutic impact distinguishes it
from traditional biopharmaceutical therapies focused on a single
mechanism of benefit. The therapy represents a unique
"off-the-shelf" stem cell product that can be manufactured in a
scalable manner, may be stored for years in frozen form, and is
administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent safety profile
demonstrated in clinical studies, MultiStem therapy could provide a
meaningful benefit to patients, including those suffering from
serious diseases and conditions with unmet medical need.
About Athersys
Athersys is an international biotechnology company engaged in
the development of therapeutic products designed to extend and
enhance the quality of human life. The Company is developing its
MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and
cardiovascular disease areas, and has several ongoing clinical
trials evaluating this potential regenerative medicine product.
Athersys has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. More information is available at
www.athersys.com.
William (B.J.) LehmannPresident and Chief Operating OfficerTel:
(216) 431-9900bjlehmann@athersys.com
Karen HunadyDirector of Corporate Communications &
Investor RelationsTel: (216) 431-9900khunady@athersys.com
David SchullRusso Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024